Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials

Figures & data

Figure 1 (A and B) Mean ABR, any bleeding, after matching for all selected baseline variables;^†forest plot represents relative treatment effects presented as IRR with 95% CI.

Notes: ^†Age, number of target joints, proportion of patients with prior prophylaxis, ethnicity (proportion of white patients) and treatment duration (weeks); ^‡Effective sample size; ^¶Data from HAVEN 3; ^§Data from HAVEN 4

Abbreviations: ABR, annualized bleeding rate; CI, confidence interval; IRR, incidence rate ratio; Q1W, once a week; Q2W, once every 2 weeks; Q4W, once every 4 weeks.

Figure 2 (A and B) Proportion of patients with zero bleeds after matching for all selected baseline variables; ^†forest plot represents relative treatment effects presented as OR with 95% CI.

Notes: ^†Age, number of target joints, proportion of patients with prior prophylaxis, ethnicity (proportion of white people) and treatment duration (weeks); ^‡Effective sample size; ^¶Data from HAVEN 3; ^§Data from HAVEN 4.

Abbreviations: CI, confidence interval; OR, odds ratio; Q1W, once a week; Q2W, once every 2 weeks; Q4W, once every 4 weeks.